Healthcare Sales & Marketing Network News: Dystrophic Epidermolysis Bullosa

Searching News Database: Dystrophic Epidermolysis Bullosa

HSMN NewsFeed - 21 Oct 2020
FDA Grants Fast Track Status to Aegle Therapeutics' AGLE-102 for the Treatment of Dystrophic Epidermolysis Bullosa
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 29 Sep 2020
Aegle Therapeutics Completes $6.5M Series A Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 2 Apr 2018
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Dec 2016
Fibrocell Announces Leadership Changes
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Nov 2014
Agilis Biotherapeutics Names Former Shire Executive Dr. Gregory Robinson as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Sep 2006
FDA Issues Approvable Letter to Ortec for Use of Cryopreserved OrCel(R) in Epidermolysis Bullosa Patients' Hand Reconstructions and Donor Sites
Regenerative Medicine FDA

HSMN NewsFeed - 17 Jul 2006
Cambrex and Ortec Submit to FDA a Humanitarian Device Exemption (HDE) for OrCel(R) to Treat Epidermolysis Bullosa Patients
Devices

HSMN NewsFeed - 6 Jul 2006
Ortec Issues Update on Its Three Technology Platforms for Regenerative Medicine and Stem Cells
Regenerative Medicine

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.